Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).
Similar Posts
Why Not Natural, Houston, Texas, is Recalling its Why Not Natural Organic Moringa – Green Superfood because of Possible Health Risk
Why Not Natural, Houston, Texas, is voluntarily recalling its Why Not Natural Organic Moringa – Green Superfood because they may be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened imConcord Biotech Limited – 04/28/2025-05/02/2025
Concord Biotech Limited – 04/28/2025-05/02/2025. Country: India. Record Type: 483EnviroServe Chemicals & Cleaners Ltd. – 674090 – 09/09/2024
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/MisbrandedFusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical. Los Angeles, CA. Amended 483 issued 12/20/2019
Task Description Request Please post to the ORA Electronic Reading Room
Record Date 12/20/2019
Short Title (70 char) Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical. Los Angeles, CA. Amended 483 issued 12/20/2019
FEI Number 3013341563
Firm Name Fusion IV Pharmaceuticals, Inc.
Record Type AmeHofood99 Inc Recalls Enoki Mushroom Due to Possible Health Risk
Hofood99 Inc of Brooklyn, NY 11231 is recalling its 200g packages of Enoki Mushroom, because they may be contaminated with Listeria monocytogenesFDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).